EP0363212A2 — Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
Assigned to Bayer Pharma AG · Expires 1990-04-11 · 36y expired
What this patent protects
Novel heterocyclic compounds, which are represented by the following general formula (I), useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epo…
USPTO Abstract
Novel heterocyclic compounds, which are represented by the following general formula (I), useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative. An example is 5-[3-{4-(dibenzosuberane-5-yl)piperazine-1-yl}-z-hyroxypropoxy]quinoline. <CHEM>
Drugs covered by this patent
- Vizimpro (Dacomitinib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.